Five Legal Issues Facing the Biotech Industry in 2026–27

The biotechnology industry continues to advance at remarkable speed. Artificial intelligence, gene editing, personalized medicine, advanced diagnostics, and new clinical-trial technologies are creating opportunities that would have seemed impossible only a few years ago.
​
However, rapid innovation also creates legal and regulatory uncertainty. Biotech companies must protect intellectual property, meet evolving regulatory requirements, secure sensitive data, and manage contractual obligations—all while competing for funding and bringing products to market.

Here are five legal issues biotech companies should closely monitor in 2026 and 2027.

1. Regulatory Oversight of Artificial Intelligence
Artificial intelligence is being used throughout the biotech industry to identify drug candidates, analyze clinical data, improve manufacturing, and support regulatory submissions.
The legal challenge is establishing that an AI model is reliable, properly validated, and appropriate for its intended use.
The FDA’s current framework emphasizes risk-based credibility assessments when AI-generated data supports decisions about the safety, effectiveness, or quality of drugs and biological products. FDA and the European Medicines Agency have also outlined good AI practices involving data governance, documentation, human oversight, performance testing, and lifecycle management. FDA: Artificial Intelligence for Drug Development
Biotech companies using AI should be prepared to explain:

• Where training and validation data originated
• Whether the company has permission to use the data
• How bias and errors are detected
• Who is responsible for reviewing AI-generated results
• How model changes are documented
• Whether results can be reproduced and independently verified

Companies should avoid treating AI as an isolated technology project. Its use should be incorporated into regulatory, legal, quality-control, and risk-management programs.

2. Protecting Intellectual Property and Trade Secrets
A biotech company’s value often depends heavily on its intellectual property. Patents may protect compounds, therapies, processes, platforms, diagnostic methods, and manufacturing techniques. Trade secrets may cover formulas, research data, algorithms, laboratory methods, and development strategies.
AI-assisted research is making inventorship and ownership more complicated. Companies must be able to document the contributions of human researchers and establish clear ownership of discoveries created with the assistance of AI tools.
The USPTO has continued to address the treatment of AI-assisted inventions, while maintaining the importance of human inventorship. Biotech companies should keep detailed records showing how researchers conceived, directed, evaluated, and refined an invention.
Trade-secret protection is equally important. Risks may arise when employees leave, research partners gain access to confidential information, or data is shared with contract research organizations and technology vendors.
Companies should review:

• Employee confidentiality agreements
• Invention-assignment provisions
• Nondisclosure agreements
• Laboratory-access controls
• AI-platform terms of use
• Data-sharing agreements
• Joint-development and licensing contracts
• Procedures for departing employees

A company that cannot demonstrate reasonable efforts to protect confidential information may have difficulty enforcing its trade-secret rights

3. Data Privacy and Cybersecurity
Biotech organizations collect and store some of the most sensitive information available, including genetic data, medical histories, clinical trial results, biomarker data, and personally identifiable information.
A cybersecurity incident can lead to regulatory investigations, lawsuits, intellectual-property loss, clinical disruption, reputational damage, and notification expenses.
Compliance may involve several overlapping laws, depending on the company’s operations and location. These may include HIPAA, state consumer privacy laws, genetic privacy statutes, breach notification requirements, international data protection rules, and contractual obligations imposed by research partners.
Companies should understand:

• What personal and research data they collect
• Where the information is stored
• Who has access to it
• How long it is retained
• Whether participants provided appropriate consent
• Which third parties receive the data
• How a breach will be detected and reported

Cybersecurity should extend beyond the company’s internal network. Cloud providers, laboratories, software vendors, clinical research organizations, and other partners may create additional exposure.

4. Clinical-Trial Compliance and Participant Protection
Clinical trials are becoming more decentralized and technology-driven. Wearable devices, remote monitoring, electronic consent, AI-based analysis, and real-time reporting can make trials more efficient, but they also introduce new legal responsibilities.
The FDA has recently advanced initiatives involving real-time clinical trials and technology-supported evidence collection. These developments increase the need for dependable systems, accurate data, and clearly assigned responsibilities. FDA: Real-Time Clinical Trials
Potential problems include:

• Inadequate informed consent
• Failure to protect participant privacy
• Inaccurate or incomplete trial data
• Undisclosed conflicts of interest
• Improper recruitment practices
• Unequal participant selection
• Failure to report adverse events
• Unclear responsibility among sponsors, investigators, and vendors

Contracts with clinical sites and research organizations should clearly define data ownership, reporting obligations, regulatory responsibilities, indemnification, insurance requirements, and procedures for responding to adverse events.

5. Product Liability and Insurance Requirements
Even when a biotech company follows regulatory requirements, it may still face allegations that a product caused injury, failed to perform as represented, or was accompanied by inadequate instructions or warnings.
Claims can arise during research, clinical testing, manufacturing, distribution, or after a product reaches the market. Legal costs can become substantial even when the allegations are ultimately unsuccessful.
Biotech companies should evaluate whether they need:

• General liability insurance
• Products and completed-operations coverage
• Clinical-trial liability insurance
• Errors and omissions or professional liability insurance
• Cyber liability insurance
• Directors and officers liability insurance
• Employment practices liability insurance
• Property and equipment coverage
• Pollution or environmental liability insurance
• Crime and intellectual-property protection

Contractual insurance requirements should also be reviewed carefully. Agreements with investors, landlords, research institutions, manufacturers, and clinical partners may require specific limits, endorsements, or indemnification obligations that are not automatically covered by a standard policy.

Preparing for the Risks Ahead
The legal environment for biotech companies will continue to change throughout 2026 and 2027. Businesses should not wait for a lawsuit, data breach, regulatory inquiry, or clinical setback before reviewing their risk-management programs.

A proactive approach should include regular legal reviews, strong documentation, carefully drafted contracts, vendor oversight, cybersecurity planning, intellectual property controls, and insurance coverage tailored to the company’s actual operations.

At Strive Insurance Group, we understand that biotech companies face risks that extend far beyond those of a traditional business. We can help evaluate your insurance program, identify potential coverage gaps, and develop protection that evolves with your research, funding, clinical trials, and commercialization plans.